down arrow

Mochida Pharmaceutical Co., Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3922800002
JPY
3,585.00
100 (2.87%)

Mar 24

TKS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Sumitomo Pharma Co., Ltd.
Tsumura & Co.
Towa Pharmaceutical Co., Ltd.
Suzuken Co., Ltd.
Nippon Shinyaku Co., Ltd.
Santen Pharmaceutical Co., Ltd.
Hisamitsu Pharmaceutical Co., Inc.
Mochida Pharmaceutical Co., Ltd.
JCR Pharmaceuticals Co., Ltd.
SAWAI GROUP HOLDINGS Co., Ltd.
Kaken Pharmaceutical Co., Ltd.

Why is Mochida Pharmaceutical Co., Ltd. ?

1
Poor long term growth as Net Sales has grown by an annual rate of 0.65% and Operating profit at -1.59% over the last 5 years
2
The company declared negative results in Mar'25 after flat results in Dec'24
  • INTEREST COVERAGE RATIO(Q) Lowest at 11,475.86
  • RAW MATERIAL COST(Y) Grown by 15.63% (YoY)
  • DEBT-EQUITY RATIO (HY) Highest at -22.32 %
3
Underperformed the market in the last 1 year
  • The stock has generated a return of 10.65% in the last 1 year, much lower than market (Japan Nikkei 225) returns of 36.73%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Mochida Pharmaceutical Co., Ltd. for you?

Low Risk, Low Return

Absolute
Risk Adjusted
Volatility
Mochida Pharmaceutical Co., Ltd.
10.65%
0.63
24.19%
Japan Nikkei 225
36.73%
1.30
28.24%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
0.65%
EBIT Growth (5y)
-1.59%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.39
Sales to Capital Employed (avg)
0.80
Tax Ratio
29.40%
Dividend Payout Ratio
49.89%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.13%
ROE (avg)
5.66%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
0.85
EV to EBIT
7.33
EV to EBITDA
5.38
EV to Capital Employed
0.75
EV to Sales
0.57
PEG Ratio
1.10
Dividend Yield
0.02%
ROCE (Latest)
10.22%
ROE (Latest)
4.35%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company
ROCE(HY)

Highest at 4.8%

NET PROFIT(9M)

Higher at JPY 6,342 MM

NET SALES(Q)

Highest at JPY 32,502 MM

-15What is not working for the Company
INTEREST COVERAGE RATIO(Q)

Lowest at 11,475.86

RAW MATERIAL COST(Y)

Grown by 15.63% (YoY

DEBT-EQUITY RATIO (HY)

Highest at -22.32 %

INTEREST(Q)

Highest at JPY 29 MM

Here's what is working for Mochida Pharmaceutical Co., Ltd.

Net Sales
Highest at JPY 32,502 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (JPY MM)

Net Profit
Higher at JPY 6,342 MM
than preceding 12 month period ended Dec 2025
MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months

Net Profit (JPY MM)

Here's what is not working for Mochida Pharmaceutical Co., Ltd.

Interest
At JPY 29 MM has Grown at 2,800%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Interest Coverage Ratio
Lowest at 11,475.86
in the last five periods
MOJO Watch
The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Interest
Highest at JPY 29 MM
in the last five periods and Increased by 2,800% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Debt-Equity Ratio
Highest at -22.32 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost
Grown by 15.63% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Download on App Store
Get it on Google Play
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."